Abstracts Archive - Page 682 of 2425 - ACR Meeting Abstracts

Abstract Number: 0817 • ACR Convergence 2020
Uptake of Janus Kinase Inhibitors for Management of Rheumatoid Arthritis in Australia
Geoffrey Littlejohn¹, Tegan Smith², Kathleen Tymms³, Peter Youssef⁴, Helen Cooley⁵, Sabina Ciciriello⁶, David Mathers⁷, Catherine OSullivan² and Hedley Griffiths⁸, ¹Monash Rheumatology, Clayton, VIC; OPAL Rheumatology Ltd, Sydney, NSW, Melbourne, Victoria, Australia, ²OPAL Rheumatology Ltd, Sydney, NSW, Kogarah, New South Wales, Australia, ³Canberra Rheumatology, Canberra, ACT, Canberra, Australian Capital Territory, Australia, ⁴University of Sydney, Sydney, NSW; Royal Prince Alfred Hospital, Camperdown, NSW, Camperdown, New South Wales, Australia, ⁵Hobart Private Hospital, Hobart, TAS, Taroona, Australia, ⁶Royal Melbourne Hospital, Melbourne, VIC, Melbourne, Victoria, Australia, ⁷Georgetown Rheumatology, Georgetown, NSW, Georgetown, New South Wales, Australia, ⁸Barwon Rheumatology Service, Geelong, VIC, Geelong, Victoria, Australia
Background/Purpose: JAK inhibitors (JAKi) are targeted synthetic DMARDs (tsDMARDs) with a different mode of action (MOA) to conventional synthetic and biologic DMARDs (cs and bDMARDs).…
Abstract Number: 0816 • ACR Convergence 2020
Treat-to-target Strategy in Patients with Rheumatoid Arthritis in Daily Clinical Practice -still Underused, but Superior to Routine Care: A Propensity Score Matched Analysis from the ATTRA Registry
Jakub Závada¹ and Lucie Nekvindova², ¹Revmatologický ústav, Praha 2, Czech Republic, ²Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
Background/Purpose: Treat-to-target (T2T) is a widely accepted management strategy for RA. It recommends attaining a goal of at least low disease activity (LDA) within 6…
Abstract Number: 0822 • ACR Convergence 2020
Effectiveness After Transition to SB4 (Brenzys, Etanercept Biosimilar) versus Continuation of Etanercept (ETN) Originator (Enbrel) Among Rheumatoid Arthritis (RA) Patients in Low Disease Activity: A Prospective Multinational Multicenter Observational Study
Janet Pope¹, Stephen Hall², Claire Bombardier³, Edward C Keystone⁴, Boulos Haraoui⁵, Graeme Jones⁶, Latha Naik⁷, Wei David Wu⁸, Dena Ramey⁹, Ricardo Infante¹⁰ and Carol Etzel¹¹, ¹Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ²Emeritus Research, Camberwall, Victoria, Australia, ³Institute for Work and Health, Toronto, ON, Canada, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵Rheumatology Institute of Montréal, Montreal, Canada, ⁶Menzies Institute for Medical Research, Hobart, Tasmania, Australia, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸Merck & Co., Rahway, NJ, ⁹Merck & Co., West Point, PA, ¹⁰Merck & Co., Kenilworth, NJ, ¹¹Corrona, LLC, Southborough, MA
Background/Purpose: COMPANION-B was a prospective real-world observational study designed to provide evidence on the effectiveness of SB4, a biosimilar of ETN compared to ETN originator…
Abstract Number: 0821 • ACR Convergence 2020
Gender and Discontinuation of Biologic DMARDs in Patients with Rheumatoid Arthritis: Data from the Mexican Biologics Registry
Vijaya Rivera¹, Sandra Sicsik Ayala¹, David Vega Morales², Fedra Irazoque-Palazuelos³, Dafhne Miranda Hernández¹, Julio Casasola Vargas¹, Sandra Carrillo Vázquez¹, Angélica Peña Ayala¹, Angel Castillo Ortiz¹, Omar Muñoz Monroy¹, Sergio Durán Barragán¹, Aleni Paz Viscarra¹, Estefanía Torres Valdez¹, Daniel Xibille Friedmann¹, Erick A Zamora Tehozol⁴, Luis Valdés Corona¹, Azucena Ramos Sánchez¹, Natalia Santana Portillo¹, Francisco Guerrero Díaz¹, Miguel Vazquez Zaragoza¹, Claudia Zepeda Moreno¹, Kitzia Alvarado Sánchez¹, Melanea Rivera Valencia¹, Cesar Pacheco Tena⁵ and Deshire Alpizar-Rodriguez⁶, ¹Colegio Mexicano de Reumatología, Mexico City, Mexico, ²Universidad Autónoma de Nuevo León, Garcia, Mexico, ³Centro de Investigación y Tratamiento Reumatológico S.C, Miguel Hidalgo, Mexico, ⁴Centro Médico Pensiones, Merida, Yucatan, Mexico, ⁵Universidad Autonoma de Chihuahua, Chihuahua, Chihuahua, Mexico, ⁶Colegio Mexicano de Reumatología, Mexico City, Distrito Federal, Mexico
Background/Purpose: Rheumatoid arthritis (RA) is the most common autoimmune disease and is more frequent and severe in women than in men. Symptom severity, disease progression,…
Abstract Number: 0827 • ACR Convergence 2020
Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis
Thomas Huizinga¹, Ernest Choy², Amy Praestgaard³, Hubert van Hoogstraten⁴, Patrick R LaFontaine³, Patricia Guyot⁵, Daniel Aletaha⁶, Ulf Müller-Ladner⁷, Yoshiya Tanaka⁸, Jeffrey R Curtis⁹ and Roy Fleischmann¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ³Sanofi, Cambridge, MA, ⁴Sanofi, Bridgewater, NJ, ⁵Sanofi, Chilly-Mazarin, France, ⁶Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, ⁷Department of Rheumatology and Clinical Immunology, Justus-Liebig University, Campus Kerckhoff, Bad Nauheim, Germany, ⁸The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Sarilumab, an IL-6 receptor inhibitor, and upadacitinib, a Janus kinase (JAK) 1 inhibitor, are both approved for the treatment of patients with moderately to…
Abstract Number: 0829 • ACR Convergence 2020
International Comparison of Japanese and US Cross Country Utilization of RA Medications
Hisashi Yamanaka¹, Mitsumasa Kishimoto², Kazuhisa Nakano³, Kenta Misaki⁴, Yuji Yamanishi⁵, Hiroaki Dobashi⁶, Masamitsu Natsumeda⁷, Toshiaki Miyamoto⁸, Koichi Amano⁹, Akira Sagawa¹⁰, Norihiko Koido¹¹, Corrona Japan Consortium¹², Leslie Harrold¹³, Tin-chi Lin¹³, Jeffrey Greenberg¹⁴ and Yoshiya Tanaka³, ¹Sanno Medical Center, Tokyo, Japan, Tokyo, Japan, ²Department Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ³The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴Kitaharima Medical Center, Ono, Japan, ⁵Hiroshima Rheumatology Clinic, Hiroshima, Japan, ⁶Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ⁷Mabi Memorial Hospital, Kurashiki, Japan, ⁸Seirei Hamamatsu General Hospital, Hamamatsu, Japan, ⁹Saitama Medical Center, Kawagoe, Japan, ¹⁰Sagawa Akira Rheumatology Clinic, Sapporo, Japan, ¹¹Kawasaki RA & IM Clinic, Kawasaki, Japan, ¹²Corrona Japan Consortium, Japan, Japan, ¹³Corrona, LLC, Waltham, MA, ¹⁴Corrona, LLC and NYU School of Medicine, Waltham, MA
Background/Purpose: Little is known regarding differences in DMARD utilization across countries. A better understanding is needed to contextualize findings from different countries.1 Using the same…
Abstract Number: 0824 • ACR Convergence 2020
The Comparative Effectiveness of Abatacept versus Tofacitinib After 6 Months of Treatment in Patients with RA Who Were Anti-citrullinated Protein Antibody Positive at Baseline: Results from a US National Observational Study
Leslie Harrold¹, Keith Wittstock², Sheila Kelly², Xue Han², Ying Shan¹, Page Moore¹, Lin Guo¹ and Vadim Khaychuk², ¹Corrona, LLC, Waltham, MA, ²Bristol-Myers Squibb Company, Princeton, NJ
Background/Purpose: Previous data from the Corrona RA registry, conducted in a US clinical practice setting, demonstrated that patients (pts) with RA who were ACPA+ had…
Abstract Number: 0819 • ACR Convergence 2020
The Adherence Patterns Among Patients Using Infliximab Bio-originator and Biosimilar
Joseph Alanaeme¹, Sujith Sarvesh¹, Jeffrey R Curtis² and Huifeng Yun², ¹University of Alabama at Birmingham, BIrmingham, AL, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Infliximab (INF) biosimilar was approved for multiple indications in U.S. in 2016. Although clinical trials have demonstrated that switching from infliximab bio-originator to its…
Abstract Number: 0832 • ACR Convergence 2020
PROSARA – A Prospective, Multicenter, Noninterventional Study to Evaluate the Safety and Effectiveness of Sarilumab for the Treatment of Active Rheumatoid Arthritis in Regular Care in Germany
Eugen Feist¹, Peer-Malte Aries², Silke Zinke³, Harald Burkhardt⁴, Inka Albrecht⁵, Oliver Bley⁵, Michael Obermeier⁶, Patrizia Sternad⁷, Martin Welcker⁷, Cornelia Kühne⁸, Ann-Dörthe Holst⁹, Niklas Thomas Baerlecken¹⁰ and Hans-Peter Tony¹¹, ¹Department of Rheumatology, Helios Vogelsang-Gommern, Vogelsang-Gommern, Germany, ²Rheumatologie im Struenseehaus, Hamburg, Germany, ³Outpatient Rheumatology Center Berlin-Lichtenberg, Berlin, Germany, ⁴Department of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany, Frankfurt am Main, Germany, ⁵Sanofi Aventis Deutschland GmbH, Berlin, Germany, ⁶GKM Gesellschaft für Therapieforschung, Munich, Germany, ⁷MVZ für Rheumatologie Dr. M. Welcker, Planegg, Germany, ⁸Outpatient practice, Haldensleben, Germany, ⁹Outpatient practice, Ludwigslust, Germany, ¹⁰Rheumatology Cologne Dr. N. Baerlecken/Dr. T. Karger, Cologne, Germany, ¹¹Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany
Background/Purpose: Blockade of IL-6 signaling by sarilumab has been demonstrated to be an effective treatment approach for RA. Due to strict inclusion and exclusion criteria,…
Abstract Number: 0835 • ACR Convergence 2020
Pathogenic Effect of Chronic Stress-induced interleukin-12/23p40 on Neuropsychiatric System in Lupus-prone Mouse
Nobuya Abe¹, Kenji Oku¹, Yuichiro Fujieda¹, Nobuhiko Takahashi², Kohei Karino¹, Michihito Kono¹, Masaru Kato¹, Yuki Tanaka³, Rie Hasebe⁴, Olga Amengual¹, Miwako Yamasaki⁵, Masahiko Watanabe⁵, Masaaki Murakami³ and Tatsuya Atsumi⁶, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ²Division of Molecular Psychoimmunology, Institute for Genetic Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ³Division of Molecular Psychoimmunology, Institute for Genetic Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ⁴Biomedical Animal Research Laboratory, Institute for Genetic Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ⁵Department of Anatomy, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ⁶Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan
Background/Purpose:Neuropsychiatric system is one of the major organs affected in systemic lupus erythematosus (SLE). However, the pathogenesis of neuropsychiatric SLE (NPSLE) has not been fully…
Abstract Number: 0836 • ACR Convergence 2020
SH3BP2 Deficiency Ameliorates Murine Systemic Lupus Erythematosus
Tomoyuki Mukai¹, Kyoko Kawahara¹, Masanori Iseki², Akiko Nagasu¹, Hajime Nagasu³, Takahiko Akagi¹, Shoko Tsuji¹, Yasuyoshi Ueki⁴, Katsuhiko Ishihara², Naoki Kashihara³ and Yoshitaka Morita¹, ¹Department of Rheumatology, Kawasaki Medical School, Kurashiki, Okayama, Japan, ²Department of Immunology and Molecular Genetics, Kawasaki Medical School, Kurashiki, Okayama, Japan, ³Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan, ⁴Department of Biomedical Sciences and Comprehensive Care, Indiana University School of Dentistry, Indianapolis, IN
Background/Purpose: The adaptor protein, Src homology 3 domain-binding protein 2 (SH3BP2), is widely expressed in immune cells, such as myeloid cells, B cells, and T…
Abstract Number: 0831 • ACR Convergence 2020
Sociodemographic, Disease, and Medication Profile of RA Patients Under 65 Years Compared with 65 Years or Older at Registry Enrollment: Real World Results from a Rheumatoid Arthritis Cohort
Mohammad Movahedi¹, Angela Cesta², Xiuying Li³ and Claire Bombardier⁴, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, Toronto, Canada, ⁴Institute for Work and Health, Toronto, ON, Canada
Background/Purpose: Age is an important factor that can affect disease course, physical function and treat to target strategy for patients with rheumatoid arthritis (RA). We…
Abstract Number: 0839 • ACR Convergence 2020
Single-Cell Transcriptomics of Mouse and Human Lupus Nephritis Identifies Conserved Myeloid Populations Across Species
Paul Hoover¹, Michael Peters², David Lieb³, Rakesh Mishra⁴, Nir Hacohen² and Anne Davidson⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Broad Institute, Boston, ³Broad Institute, Boston, MA, ⁴Feinstein Institute, Manhasset, NY, ⁵Northwell Health, New York
Background/Purpose: We recently identified novel immune cell states in the kidneys of lupus nephritis patients (Arazi et al, Nature Immunology 2019). To determine the similarities…
Abstract Number: 0834 • ACR Convergence 2020
Is Disease Severity Greater Among Patients with Rheumatoid Arthritis Who Receive a Newly Approved Biologic? Real-world US Experience with Sarilumab from the ACR RISE Registry
Stefano Fiore¹, Lang Chen², Cassie Clinton², Huifeng Yun², Amy Praestgaard³, Kerri Ford³ and Jeffrey R Curtis², ¹Sanofi, Bridgewater, NJ, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Sanofi, Cambridge, MA
Background/Purpose: Patients with RA who have received multiple biologics or targeted therapies over time tend to have more refractory and more severe disease, which may…
Abstract Number: 0726 • ACR Convergence 2020
Who Ordered the Stiff One? Characteristics of Polyarticular Juvenile Idiopathic Arthritis Patients Associated with the Presence and Increased Duration of Joint Stiffness
Nayimisha Balmuri¹, Victoria Cooley², Linda Gerber², Susan Goodman³, Bella Mehta³ and Karen Onel⁴, ¹Hospital for Special Surgery, new york, NY, ²Weill Cornell Medicine, NY, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Pediatric Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Joint stiffness as a sign of intra-articular inflammation may be an early presenting symptom of JIA. Studies following pain in chronic disease have shown…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].